481 results about "Cardiac arrhythmia" patented technology

The invention discloses a convolutional neural network information processing method for heart function dynamic monitoring, and belongs to the technical field of medical detection and monitoring. Comprising the following steps that multi-mode electrocardiosignal data and current physiological state parameters of a patient are obtained, and initial configuration of the intelligent heart function monitoring device is obtained; determining the signal quality grade of each signal channel, and generating a dynamic filtering adjustment strategy of the multi-modal signal acquisition module; configuring a feature extraction strategy of a double-branch convolutional neural network module based on the signal features of the target analysis signal segment and the physiological state parameters; performing multi-scale time sequence feature extraction and frequency domain autonomic nerve regulation feature extraction on the target analysis signal segment by using a double-branch convolutional neural network module according to a feature extraction strategy; executing arrhythmia classification, heart rate variability parameter quantification, heart function evaluation grade and graded early warning tasks, and outputting multi-stage intelligent early warning information from normal monitoring, potential risk and abnormal early warning to an emergency state.

The invention relates to the technical field of electrocardiosignal analysis, and discloses a long-sequence electrocardiosignal disease recognition system based on a Transform architecture. The core defects that in traditional electrocardiogram analysis, waveform integrity is damaged by fixed window segmentation, a lead space topological relation is neglected, and long sequence modeling efficiency is low are overcome, a P-QRS-T waveform structure is completely reserved through the heart beat adaptive segmentation technology, and the fixed window truncation risk is eliminated; the lead anatomical topology and the space-time coding are fused, and multi-lead electrophysiological association is modeled; long sequence efficient processing is realized based on hierarchical sparse Transform, and the recognition sensitivity of complex pathologies such as arrhythmia and myocardial ischemia is improved; in combination with gradient directional regulation and control and a streaming processing mechanism, the clinical real-time requirement is met while the diagnosis accuracy is guaranteed, and finally, reliable, efficient and universal intelligent decision support is provided for early warning of heart diseases through lightweight deployment of an adaptive mobile terminal.

The invention discloses an abnormal heart beat detection method and system based on a magnetic cardiogram, and relates to the technical field of medical data processing, and the method comprises the steps: carrying out the preprocessing of original magnetic cardiogram data; magnetic cardiogram features are extracted based on discrete wavelet transform, model parameters are adjusted, and an abnormal heart beat detection model is obtained; and judging whether abnormal heart beat exists or not and the position. According to the method, the problem that the magnetocardiogram data lacks a large number of heart beat level labeling samples is effectively solved, dependence on labeling data is reduced, automatic, efficient and accurate detection of abnormal heart beats is achieved, the good clinical application prospect is achieved, and powerful support can be provided for early screening, auxiliary diagnosis and risk assessment of arrhythmia.

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

The invention discloses a multifunctional cardiovascular monitoring system which comprises an electrocardiosignal acquisition module, a conduction block feature extraction module, an arrhythmia classification processing module, a cardiac function parameter calculation module, an intelligent diagnosis analysis module and a monitoring data output module. The electrocardiosignal acquisition module acquires and transmits original signals, the conduction block feature extraction module extracts feature parameters by using an exclusive algorithm, the arrhythmia classification processing module obtains classification results through a multi-dimensional classifier, and the cardiac function parameter calculation module generates calibration parameters by using a dynamic calibration model in combination with the classification results. The intelligent diagnosis analysis module generates diagnosis data through comprehensive analysis of the auxiliary platform, and the monitoring data output module processes the data and then outputs the data. The system realizes module cooperation and data interaction, improves the monitoring efficiency, guarantees data accuracy by using a professional algorithm and a model, and provides reliable support for clinical cardiovascular monitoring.

The invention provides an arrhythmia auxiliary diagnosis method and system fusing spatial-temporal features and physiological constraints, relates to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, feature extraction is insufficient, spatial-temporal relevance, doctor interpretability and constraint are lacked, and a model is poor in recognition capacity for complex arrhythmia. The method comprises the following steps: acquiring an original 12-lead electrocardiosignal, and normalizing the original 12-lead electrocardiosignal; inputting the normalized electrocardiosignals into an initial convolution module to extract initial features; the initial features are sequentially input into four-stage residual error convolution modules for feature extraction, and fourth-stage features are obtained; performing adaptive average pooling on the fourth-stage features, and outputting an arrhythmia classification probability through a full-connection layer; and according to the arrhythmia classification probability, obtaining an auxiliary diagnosis result of arrhythmia. According to the method, the defects in the prior art are overcome, and the recognition capability of the model on complex arrhythmia is improved.

The embodiment of the invention provides a disease dynamic prediction method and device based on multi-source factors, a medium and a program product, and relates to the field of intelligent medical treatment. Through adaptive segmentation normalization and multi-source feature fusion technologies, the heterogeneity problem of multi-source physiological data is effectively solved, and the robustness of feature expression is remarkably improved while key physiological events are reserved; according to the dynamic prediction model based on the space-time-disease association tensor and the disease collaborative gating, explicit modeling of the three-dimensional relationship of the disease category, the physiological index and the time step is realized for the first time, so that a specific physiological index time sequence mode dependent on diseases such as arrhythmia and the like is accurately captured; the accuracy of multi-label prediction is greatly improved through coding disease co-occurrence prior; in combination with a dynamic width full-connection layer and a gradient-driven adaptive optimization strategy, the model can automatically adjust a network structure and training parameters according to the complexity of input features, and the accuracy is improved.

The invention discloses an arrhythmia detection method based on a pulse neural network. The method comprises the following steps: performing incremental modulation pulse coding and pooling operation on a target electrocardiosignal to obtain a corresponding pulse sequence; and inputting the pulse sequence into a trained multi-level pulse neural network classification model to obtain an arrhythmia detection result. Wherein the multi-level pulse neural network classification model comprises a weight sharing layer and a plurality of cascaded classifiers, the weight sharing layer is used for extracting electrocardiosignal feature information from the pulse sequence, and the plurality of classifiers are used for obtaining an arrhythmia detection result based on the electrocardiosignal feature information. According to the method, on the premise that the accuracy is equivalent, the classification result is more refined, and the requirements for hardware storage resources and computing resources are reduced.

An assessment of basal cardiac fitness uses noninvasively obtained physiological measures to determine the presence of a basal physiological state and cardiometric measures to determine cardiac fitness. In the presence of preload independence and cardiac vagal control, cardiometric signals are acquired that are sensitive to cardiac function and include information indicative of the opening and closing of the individual's aortic valve. The cardiometric signals are analyzed by a cardiac fitness assessment system for the determination of basal cardiac fitness. The invention assures preload independence through the assessment of observational physiological parameters or the use of physiological parameters obtained following alterations in venous return. The invention assures the presence of cardiac vagal control by assessment of measured parameters, including the presence of respiratory sinus arrhythmia. The resulting test is specific for cardiac function without dependencies on physical activities associated with heart rate elevation or respiratory capabilities.

The invention relates to an ECG arrhythmia classification method based on time-frequency attention enhancement and heterogeneous fusion driving. The method comprises the following steps: acquiring an original ECG signal; de-noising and overlapping slicing are carried out on the original ECG signal to obtain an ECG signal segment with a fixed length; performing time-frequency attention enhancement on the ECG signal segments to obtain time-frequency fusion ECG features; constructing a heterogeneous fusion network, and fusing channel information and position information into time-frequency fusion ECG features; constructing a full-connection network layer driven by heterogeneous fusion, fusing the key features extracted from different scales, and generating a prediction probability distribution vector; an arrhythmia recognition model is constructed based on time-frequency attention enhancement, a heterogeneous fusion network and a full-connection network layer driven by heterogeneous fusion, a loss function is designed, and ECG signal arrhythmia classification is achieved. According to the method, accurate ECG signal classification in a complex scene is realized, and the robustness of the model to individual difference and noise interference is enhanced.

A force sensor assembly for use in the field of cardiac ablation, for the ablation-based treatment of atrial fibrillation and other cardiac arrhythmias. Various embodiments of the disclosure are directed to a catheter distal force sensor for measuring catheter tip-to-endocardial wall force by measuring displacement of irradiation patterns sensed with a two-dimensional imaging sensor. The disclosed devices sense an array of irradiation pattern characteristics, including changes in size and location of irradiation shapes of the irradiation pattern. In some embodiments, multiple irradiation spots are tracked with the two-dimensional imaging sensor to infer the components of a reaction force vector acting the force sensor assembly. The disclosed force is designed to accommodate typical catheter tip dimensions, the outer diameter of these usually being less than or equal to 3 mm.

Devices, systems and methods are provided for treating target tissue with pulsed electric field energy in a manner that does not induce cardiac arrhythmias such as fibrillation of the heart and therefore negates any need for cardiac synchronization of energy delivery. Cardiac synchronization is typically employed to avoid delivering energy during portions of the cardiac cycle that are vulnerable to inducing fibrillation. Thus, herein parameters are manipulated to reduce the probability of inducing an arrhythmia. Typically, high voltage energy can trigger a premature action potential within the cardiac muscle as the delivered energy increases the cardiac muscle cell membrane permeability allowing ion transport, which can induce cardiac arrhythmias, especially ventricular fibrillation. However, both shorter pulse durations (i.e. higher frequencies such as 100-600 kHz) and biphasic waveform shapes theoretically and practically reduce the probability of inducing an arrhythmia.

A wearable defibrillator for use in dry and non-dry locations includes a harness, ECG sensing electrodes, therapy electrodes configured to deliver defibrillating shocks, and a user interface pod configured to be attached to the harness. The user interface pod includes a speaker configured to provide an audible alarm and one or more buttons configured to be pressed by the patient to indicate the patient is conscious. The wearable defibrillator also includes a waterproof or water-resistant control unit configured to determine whether the patient is experiencing a cardiac arrhythmia, issue the audible alarm, and deliver the defibrillating shocks. The wearable defibrillator further includes a connection pod configured to electrically couple the therapy electrodes to the control unit. The user interface pod is configured to be electrically coupled to the control unit via a waterproof removable connector, which forms a water-tight seal with the control unit when connected to the control unit.

A plurality of catheter-based ablation apparatus embodiments are provided that address several areas of atrial target tissue and which feature firm and consistent ablation element to tissue contact enabling the creation of effective continuous lesions.

A method for determining a location of an arrhythmogenic focus 632 in or near a heart 101 includes positioning a locator assembly 100 in the heart 101, the locator assembly 100 including a plurality of electrodes 102 for receiving electrical signals from the heart 101, generating a first signal array 733 from the electrical signals received by the plurality of electrodes 102 to determine an actual location of the arrhythmogenic focus 632, artificially stimulating the heart 101 based on the actual location determined by the first signal array 733 to generate a second signal array 735, and ascertaining the actual location of the arrhythmogenic focus 632 by comparing the first signal array 733 to the second signal array 735. In some embodiments, the locator assembly 100 includes a plurality of bipolar electrodes 102.

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

Wearable electrocardiogram (ECG) systems configured to record ECG from ears (auricular ECG systems), fingers (ear-finger or finger-finger ECG systems) or toes, comprising a processing unit configured to analyze the ECG data to detect serious cardiac arrhythmias or impending serious cardiac arrhythmia. Automatic anti-arrhythmia systems comprise one of the ECG systems and a transcutaneous auricular vagus nerve stimulation (taVNS) unit. When serious cardiac arrythmias are detected, the anti-arrhythmia systems may automatically send pre-determined electric stimuli to a vagus nerve to alleviate or stop the cardiac arrhythmias. The ECG electrodes and the stimulating electrode of the taVNS unit are located on a surface of a housing structure made of flexible elastic and adaptable material such that these electrodes will be naturally and snugly contacting the wearer's skin. These wearable ECG and anti-arrhythmia systems are suitable for easy self-installation, self-removal and daily ambulatory use.

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

According to an aspect, an improved modular wearable medical device for monitoring a patient's ECG signals and providing therapeutic shocks in the event of a cardiac arrhythmia is provided. The device includes a garment, a plurality of ECG sensing electrodes that are permanently coupled at first predetermined locations on the garment, at least one pocket or receptacle disposed on the garment and configured to removably secure a module with device electronics within a housing to the garment, a plurality of wires or cables permanently integrated into the garment and operably coupling the plurality of permanently coupled ECG sensing electrodes with the sensor interface module, a plurality of therapy electrodes removably coupled to second predetermined locations on the garment, gel deployment circuitry, one or more capacitors, and a therapy control module configured to control the provision of the therapeutic shocks.

A smart watch to detect a presence of an arrhythmia of a user is disclosed. The smart watch comprising: a processing device and a photoplethysmography (“PPG”) sensor operatively coupled to the processing device, an ECG sensor comprising two or more ECG electrodes and operatively coupled to the processing device, a display operatively coupled to the processing device, and a memory, operatively coupled to the processing device. The memory may have instructions stored thereon that, when executed by the processing device, cause the processing device to: receive PPG data from the PPG sensor, receive ECG data from the ECG sensor, detect, based on the PPG data and the ECG data simultaneously, the presence of an arrhythmia, and provide one or more recommendations to the user based on the PPG data and the ECG data.

Electrocardiography (ECG) data acquired from a subject and processed with a machine learning model to determine whether the subject has a particular cardiac condition, such as a cardiac arrhythmia, myocardial ischemia and / or myocardial infarction, or the like. The machine learning model generates classified feature data that are indicative of the presence and / or likelihood of a particular cardiac condition.

This application provides a basket catheter, which includes flexible circuit strips, an elastic support, basket electrodes, and a core rod. The flexible circuit strips are respectively arranged on the inner and outer surfaces of the elastic support, and multiple basket electrodes are disposed on the flexible circuit strips. The basket electrodes can be switched between a contracted state and an expanded state by operating the core rod. The basket electrodes on the inner surface of the elastic support are configured not to contact tissue. Accurate localization of key conduction areas through high-density sampling within the cardiac chambers allows for a clearer elucidation of the arrhythmia matrix, thereby providing better mapping and / or ablation results.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

The invention belongs to the technical field of biological medicine, and discloses an injectable hydrogel combined reagent, self-curing conductive hydrogel and application thereof. The injectable hydrogel combined reagent provided by the invention comprises a solution A and a solution B, the solution A is a first precursor solution formed by dissolving modified poloxamer PFUDAm and ammonium persulfate in deionized water; the solution B is a second precursor solution formed by dissolving N-isopropylacrylamide NIPAM, ferrous gluconate and PEDOT: PSS in deionized water, after the injectable hydrogel combined reagent is mixed in a duplex injection mode, PFUDAm, poly (N-isopropylacrylamide) and PEDOT: PSS are subjected to an oxidation-reduction reaction of ammonium sulfate and ferrous gluconate to initiate polymerization, and the self-curing conductive hydrogel is constructed. The self-curing conductive hydrogel has controllable curing time, and the self-curing conductive hydrogel has excellent swelling resistance, conductivity and good elasticity and toughness, and is expected to be combined with a cardiac pacemaker to be applied to treatment of arrhythmia.

Implantable medical devices and methods that utilize a sensing circuit to sense cardiac activity (CA) signals and an accelerometer to obtain accelerometer data. Memory stores program instructions and device parameters associated with a collection of ventricular arrhythmia (VA) therapies. A processor analyzes the CA signals over one or more cardiac beats, determines a VA episode based on the analysis of the CA signals, determines the VA episode to be hemodynamically stable or unstable based on at least one of the accelerometer data or the CA signals, selects a first VA therapy from the collection of VA therapies based on whether the VA episode is hemodynamically stable or unstable, and apply the first VA therapy using at least one of the at least two coils.

Particle or hadron therapy is used on abnormal tissue using carbon atoms, protons, or helium atoms run through a linear accelerator and then directed at the target in the body. This can be used to treat, for example, atrial fibrillation, ventricular tachycardia, hypertension, seizures, gastrointestinal maladies, etc. Contouring and gating may be used to account for cardiac and respiratory motion, helping reduce collateral damage.

Ventricle-from-atrium (VfA) devices, systems, and methods may be configured to detect a tachyarrhythmia. For in-stance, an atrial event rate may be compared to a ventricular rate to determine whether a patient's heart is undergoing a tachyarrhythmia. Further, it may be determined whether the tachyarrhythmia is a supraventricular tachycardia or ventricular tachycardia prior to delivering therapy to treat the tachyarrhythmia.

Phospholamban (PLN) is a critical regulator of calcium cyclin and contractility in the heart. The deletion of Arginine 14 of the phospholamban gene (R14del) is associated with the pathogenesis of an inherited form of cardiomyopathy with prominent arrhythmias. Although the genetic etiology is well defined, there are currently no therapies for this rare disease. This disclosure provides an allele-specific silencing approach by interfering RNA (RNAi) to reduce the expression levels of the R14del allele of the PLN gene.

An arrhythmia type inference device includes: an obtaining section that obtains a target signal waveform indicating a time-series change in the area of a region, which is at least one of a left atrium, a left ventricle, a right atrium, and a right ventricle, the target signal waveform being generated by analyzing an image of a heart of a target subject; and an inference section that infers the type of tachyarrhythmia suffered by the target subject based on the shape of the target signal waveform having a frequency in a frequency band higher than a reference frequency band predetermined as a normal range. This allows the arrhythmia type inference device to accurately infer the type of tachyarrhythmia from the image obtained by image-capturing of the heart.